Know Cancer

forgot password

A Phase II Trial of Vinflunine as Salvage Chemotherapy in Hormone Refractory Prostate Cancer (HRPC)

Phase 2
18 Years
Not Enrolling
Prostate Cancer

Thank you

Trial Information

A Phase II Trial of Vinflunine as Salvage Chemotherapy in Hormone Refractory Prostate Cancer (HRPC)

This is a non-randomized (single-arm), open-label, multi-center, single-agent, Phase II
study of vinflunine as second- or third-line treatment of subjects with HRPC. The primary
objective of the study is to evaluate the efficacy of vinflunine in the salvage treatment,
as measured by PSA Response Rate endpoint.

The primary objective of this study is as follows:

To evaluate the efficacy (as measured by the PSA response rate) of IV vinflunine
administered q3w in HRPC patients who have progressed after one or two previous chemotherapy

Secondary Objectives

The secondary objectives of this study are as follows:

- To evaluate the efficacy of IV vinflunine administered q3w in HRPC patients who have
previously received chemotherapy (one or two regimens), as measured by:

- Time to PSA progression

- Overall survival

- Palliative response in patients with an Analgesic Score (AS) ≥10 and stable
baseline pain

- Health-Related Quality of Life

- To assess the efficacy (as measured by the PSA response rate) of IV vinflunine in HRPC
patients based on their response to prior chemotherapy

- Chemotherapy responsive - previous response to most recent chemotherapy regimen lasting
>2 months after completion.

- Chemotherapy refractory - failure to respond to, or progression during or within three
months of completing last chemotherapy.

- To assess the response rate to IV vinflunine in the subset of patients with measurable
disease, as measured by traditional Response Evaluation Criteria in Solid Tumors
(RECIST) criteria (Therasse et al. 2000).

- To evaluate the safety of IV vinflunine administered every three weeks in HRPC patients
who have previously received chemotherapy.

Inclusion Criteria:

Men age 18 years of age or older who have HRPC are eligible for this study based on the
following inclusion criteria:

1. Histologically confirmed adenocarcinoma of the prostate.

2. Progressive hormone refractory locally advanced or metastatic disease.

- (Definition of HRPC): Clinical or serological evidence of disease progression
despite adequate anti-androgen therapy, documented by castrate levels of serum
testosterone (<50 ng/mL).

- Patients on medical castration therapy should continue on treatment to maintain
castrate levels of serum testosterone. Patients receiving anti-androgen or
estrogen therapy should either be maintained on it, or have documented
progression 4 weeks after withdrawal of all agents (except nilutamide and
bicalutamide), which requires 6 weeks.

3. Disease Progression, documented by any of the following:

- PSA Progression, documented by an elevated PSA level (>5 ng/mL), which has risen
serially from the baseline PSA value (PSA value #1) on two occasions, each at
least 1 week apart (these will be considered PSA values #2 and #3). (Note: if
the level of PSA value #3 is less than the level of PSA value #2, a subsequent
PSA value must be obtained (PSA value #4) at least 1 week after PSA value #3 was
measured. In order for this event to be considered a PSA progression, the level
of this final PSA value (PSA value #4) must be greater than the PSA level that
was observed for PSA value #2.

- Progressive metastatic prostate carcinoma, documented by computed tomography
(CT), magnetic resonance imaging (MRI), or radiograph of non osseous lesions
(see Section 7.2).

- Bone Scan Progression, documented by the appearance of at least one or more new
lesions that are not believed to be secondary to tumor flare phenomenon.

4. Patients with bone only disease must have a PSA level >=5 ng/mL; patients with stable
lesions must have evidence of PSA progression. Patients must have radiographically or
clinically demonstrable metastatic disease.

5. Receipt of either 1 or 2 previous chemotherapy regimens; one of these regimens must
have included docetaxel.

6. ECOG performance status of 0-2.

7. Adequate bone marrow function, defined by: white blood cells >=3,500/uL, hemoglobin
>=8 g/dL, platelet count >=100,000/uL.

8. Adequate renal function, defined by: serum creatinine <1.8 mg/dL, or calculated or
measured creatinine clearance (GFR) of >=60 cc/min. Patients with a creatinine
clearance of >30 mL/min but <60 mL/min may also be enrolled, but will require an
initial adjusted dose (see Section 5.1)

9. Adequate hepatic function, defined by: total bilirubin <1.5 x the upper limit of
normal, AST <2 x the upper limit of normal.

10. Patients must be able to comprehend the nature of the study and provide written
informed consent.

11. Partners of women of childbearing potential must use effective contraception while on
treatment and for at least 3 months thereafter. Women of childbearing potential
include females who have experienced menarche and have not undergone successful
surgical sterilization (hysterectomy, bilateral tubal ligation, or bilateral
oophorectomy) or are not post-menopausal (i.e., amenorrhea >12 months).

12. Patients on bisphosphonate therapy (at the discretion of the investigator).

Exclusion Criteria:

1. History of other prior malignancy in the past 5 years (excluding resected basal cell
or squamous cell skin cancer).

2. History of second- or third-degree heart block, uncontrolled angina, uncontrolled
hypertension, or recent myocardial infarction or congestive heart failure (New York
Heart Association Class III-IV) within the past 6 months (see Appendix F)

3. Cerebral vascular accident within the past 6 months.

4. Peripheral neuropathy > grade 2 per Common Terminology Criteria for Adverse Events
(CTCAE) v3.0.

5. Patients with rising PSA but no demonstrable metastases.

6. Previous radiotherapy, outside of standard portals, utilized for prostate cancer (if
total amount of radiotherapy encompasses >25% of bone marrow containing osseous

7. Prior therapy with Strontium 90, Samarium 150, or other injectable therapeutic

8. History of prior allergic reaction to any vinca alkaloid.

9. Use of chemotherapy or investigational drugs within 4 weeks prior to the first dose
of study drug.

10. Treatment with ketoconazole, itraconazole, ritonavir, amprenavir, or indinavir within
4 weeks prior to the first dose of study drug.

11. Previous treatment with an anthracycline.

12. Patients who are unable to receive chemotherapy on a basis of once every three weeks
as a result of physical, environmental, or co existent medical problems.

Type of Study:


Study Design:

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

PSA Response Rate, Defined as the Percentage of Patients With an Objective Decrease in PSA and/or Experience an Objective Benefit From Treatment.

Outcome Time Frame:

18 months

Safety Issue:


Principal Investigator

John D. Hainsworth, M.D.

Investigator Role:

Study Chair

Investigator Affiliation:

Sarah Cannon Research Institute


United States: Food and Drug Administration

Study ID:




Start Date:

May 2007

Completion Date:

January 2009

Related Keywords:

  • Prostate Cancer
  • Prostate Cancer
  • Hormone Refractory
  • Vinflunine
  • Salvage Chemotherapy
  • Prostatic Neoplasms



Florida Hospital Cancer Institute Orlando, Florida  32804
South Texas Oncology and Hematology San Antonio, Texas  78229
Florida Cancer Specialists Fort Myers, Florida  33901
Northeast Georgia Medical Center Gainesville, Georgia  30501
Consultants in Blood Disorders and Cancer Louisville, Kentucky  40207
Integrated Community Oncology Network Jacksonville Beach, Florida  32250
Peninsula Cancer Institute Newport News, Virginia  23601
Tennessee Oncology, PLLC Clarksville, Tennessee  37043
Oncology Hematology Care Cincinnati, Ohio  45242
Consultants in Medical Oncology and Hematology Drexel Hill, Pennsylvania  19026
Chattanooga Oncology Hematology Associates Chattanooga, Tennessee  37404
Associates in Hematology Oncology Chattanooga, Tennessee  37404